Novel antitumor strategies using cytokine PEDF for prostate cancer therapy

Olga Cain, Sofia H. Bergström, Brennen Comeau, Todd Emrick, Marxa L. Figueiredo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Prostate cancer is the most common solid tumor affecting men in the United States and Western Europe. Currently, therapeutic options remain limited and novel therapies are needed that can provide low toxicity and high therapeuticindex. One promising new agent is a potent inhibitor of angiogenesis with anti-metastatic activities, the pigment epithelium-derived factor (PEDF). Some additional functions of PEDF that augment its promise as a new therapeutic include its pro-apoptosis (tumor cells and tumor-associated endothelial cells) and potential pro-immunogenic (cytotoxic macrophages) activities. We will discuss findings by several groups using PEDF as an efficient therapeutic following many delivery strategies including gene, protein, peptide, or cell-based therapy. PEDF also has potential to serve as a proteomics biomarker for prostate cancer progression, as downregulated levels could help predict metastatic potential of tumors. We will provide an overview of the potential and promise for achieving translation of PEDF therapeutics for the treatment of advanced prostate cancer.

Original languageEnglish (US)
Pages (from-to)277-298
Number of pages22
JournalCurrent Angiogenesis
Volume1
Issue number4
StatePublished - 2012

Fingerprint

Prostatic Neoplasms
Cytokines
Neoplasms
Therapeutics
Angiogenesis Inhibitors
Cell- and Tissue-Based Therapy
Proteomics
pigment epithelium-derived factor
Down-Regulation
Endothelial Cells
Biomarkers
Macrophages
Apoptosis
Peptides
Proteins

Keywords

  • Delivery
  • Gene
  • PEDF
  • Peptide
  • Prostate cancer
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cain, O., Bergström, S. H., Comeau, B., Emrick, T., & Figueiredo, M. L. (2012). Novel antitumor strategies using cytokine PEDF for prostate cancer therapy. Current Angiogenesis, 1(4), 277-298.

Novel antitumor strategies using cytokine PEDF for prostate cancer therapy. / Cain, Olga; Bergström, Sofia H.; Comeau, Brennen; Emrick, Todd; Figueiredo, Marxa L.

In: Current Angiogenesis, Vol. 1, No. 4, 2012, p. 277-298.

Research output: Contribution to journalArticle

Cain, O, Bergström, SH, Comeau, B, Emrick, T & Figueiredo, ML 2012, 'Novel antitumor strategies using cytokine PEDF for prostate cancer therapy', Current Angiogenesis, vol. 1, no. 4, pp. 277-298.
Cain O, Bergström SH, Comeau B, Emrick T, Figueiredo ML. Novel antitumor strategies using cytokine PEDF for prostate cancer therapy. Current Angiogenesis. 2012;1(4):277-298.
Cain, Olga ; Bergström, Sofia H. ; Comeau, Brennen ; Emrick, Todd ; Figueiredo, Marxa L. / Novel antitumor strategies using cytokine PEDF for prostate cancer therapy. In: Current Angiogenesis. 2012 ; Vol. 1, No. 4. pp. 277-298.
@article{7927cb299630461ba62213ea1201dc80,
title = "Novel antitumor strategies using cytokine PEDF for prostate cancer therapy",
abstract = "Prostate cancer is the most common solid tumor affecting men in the United States and Western Europe. Currently, therapeutic options remain limited and novel therapies are needed that can provide low toxicity and high therapeuticindex. One promising new agent is a potent inhibitor of angiogenesis with anti-metastatic activities, the pigment epithelium-derived factor (PEDF). Some additional functions of PEDF that augment its promise as a new therapeutic include its pro-apoptosis (tumor cells and tumor-associated endothelial cells) and potential pro-immunogenic (cytotoxic macrophages) activities. We will discuss findings by several groups using PEDF as an efficient therapeutic following many delivery strategies including gene, protein, peptide, or cell-based therapy. PEDF also has potential to serve as a proteomics biomarker for prostate cancer progression, as downregulated levels could help predict metastatic potential of tumors. We will provide an overview of the potential and promise for achieving translation of PEDF therapeutics for the treatment of advanced prostate cancer.",
keywords = "Delivery, Gene, PEDF, Peptide, Prostate cancer, Therapy",
author = "Olga Cain and Bergstr{\"o}m, {Sofia H.} and Brennen Comeau and Todd Emrick and Figueiredo, {Marxa L.}",
year = "2012",
language = "English (US)",
volume = "1",
pages = "277--298",
journal = "Current Angiogenesis",
issn = "2211-5528",
publisher = "Bentham Science Publishers",
number = "4",

}

TY - JOUR

T1 - Novel antitumor strategies using cytokine PEDF for prostate cancer therapy

AU - Cain, Olga

AU - Bergström, Sofia H.

AU - Comeau, Brennen

AU - Emrick, Todd

AU - Figueiredo, Marxa L.

PY - 2012

Y1 - 2012

N2 - Prostate cancer is the most common solid tumor affecting men in the United States and Western Europe. Currently, therapeutic options remain limited and novel therapies are needed that can provide low toxicity and high therapeuticindex. One promising new agent is a potent inhibitor of angiogenesis with anti-metastatic activities, the pigment epithelium-derived factor (PEDF). Some additional functions of PEDF that augment its promise as a new therapeutic include its pro-apoptosis (tumor cells and tumor-associated endothelial cells) and potential pro-immunogenic (cytotoxic macrophages) activities. We will discuss findings by several groups using PEDF as an efficient therapeutic following many delivery strategies including gene, protein, peptide, or cell-based therapy. PEDF also has potential to serve as a proteomics biomarker for prostate cancer progression, as downregulated levels could help predict metastatic potential of tumors. We will provide an overview of the potential and promise for achieving translation of PEDF therapeutics for the treatment of advanced prostate cancer.

AB - Prostate cancer is the most common solid tumor affecting men in the United States and Western Europe. Currently, therapeutic options remain limited and novel therapies are needed that can provide low toxicity and high therapeuticindex. One promising new agent is a potent inhibitor of angiogenesis with anti-metastatic activities, the pigment epithelium-derived factor (PEDF). Some additional functions of PEDF that augment its promise as a new therapeutic include its pro-apoptosis (tumor cells and tumor-associated endothelial cells) and potential pro-immunogenic (cytotoxic macrophages) activities. We will discuss findings by several groups using PEDF as an efficient therapeutic following many delivery strategies including gene, protein, peptide, or cell-based therapy. PEDF also has potential to serve as a proteomics biomarker for prostate cancer progression, as downregulated levels could help predict metastatic potential of tumors. We will provide an overview of the potential and promise for achieving translation of PEDF therapeutics for the treatment of advanced prostate cancer.

KW - Delivery

KW - Gene

KW - PEDF

KW - Peptide

KW - Prostate cancer

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84895135495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895135495&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84895135495

VL - 1

SP - 277

EP - 298

JO - Current Angiogenesis

JF - Current Angiogenesis

SN - 2211-5528

IS - 4

ER -